Premium
A woman's choice
Author(s) -
Sparrow Margaret June
Publication year - 2004
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.2004.00190.x
Subject(s) - abortion , medicine , mifepristone , secrecy , medical abortion , reproductive health , gynecology , misoprostol , family medicine , law , political science , pregnancy , environmental health , population , genetics , biology
Abortion is now the most common gynaecological operation in New Zealand and Australia. Early legal abortion is a safe procedure whether carried out surgically or medically. In contrast, the traditional use of abortifacients has been mostly unscientific, illegal and shrouded in secrecy. Mifepristone as an option for induced abortion has only recently become available in New Zealand and is not yet available in Australia. The reasons for the delay in introducing a significant new abortion technique are political, professional, legal, socioeconomic and commercial. Istar, a not‐for‐profit company, was formed in New Zealand in 1999 to import mifepristone. The drug was approved for use in New Zealand on 30 August 2001. It was first used in October 2001 in Wellington for mid‐trimester abortions and in April 2002 for early medical abortions. Legal ambiguities were clarified in a High Court Judgment on 10 April 2003. The experience with mifepristone raises concerns about the introduction of new drugs for reproductive health care, given the commercial risks associated with their development. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists has a role to play in ensuring that safe abortion services are available for women. Advocates of women's rights in reproductive health care have made a significant impact in the last three decades and the conclusion that abortion must be the woman's choice is strongly supported.